A Phase 3 interventional study of Pioglitazone and Metformin and Glimepiride and Metformin in Diabetes Mellitus and Dyslipidemias, sponsored by Takeda. Completed at 64 sites in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2010-10-06.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 — 7 open to participants now, 8 under way, 1 of them phase 3. Pioglitazone · Diabetes Mellitus, Type 2.
Among the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, this one is the 31st largest by enrollment, is one of 12 that started in 2007, is one of 31 in phase 3, and was the 50th registered.
10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →7 of the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 30–70 · Healthy volunteers
Seoul National University Bundang Hospital · Sites in Korea, Republic of
Ages 20+
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–75
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 30–70 · Healthy volunteers
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–80
By country, each count listing its studies:
Pioglitazone: first FDA approval 1999 (ACTOS), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
122 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 11 · Phase 3 33 · Phase 4 57
First in 2000; this study’s year is marked. 12 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 305 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 103 across the 122 interventional studies. Of the 96 that completed or were terminated, 31 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 122 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
105 studies in Diabetes Mellitus, Type 2 by Takeda: none open now, none under way, none of them phase 3. Of 103 finished, 69 (67%) have results posted.
Among the 105 studies in Diabetes Mellitus, Type 2 by Takeda, this one is the 48th largest by enrollment of the 85 interventional ones that give a count, is one of 13 that started in 2007, is one of 45 in phase 3, and was the 41st registered.
Takeda’s Diabetes Mellitus, Type 2 studies by the year they started, since 2000.
4 of the studies testing pioglitazone in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06989723Seoul National University Bundang HospitalPioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes | 2026-12-31 |
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
| NCT05305287The University of Texas Health Science Center at San AntonioQuantifying Hepatic Mitochondrial Fluxes in Humans | 2027-03-31 |
| NCT04501406University of FloridaLow-Dose Pioglitazone in Patients With NASH (AIM 2) | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 105 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare pioglitazone and metformin combination therapy, twice daily (BID), to glimepiride and metformin combination therapy for treating diabetic subjects with dyslipidemia.
Insulin resistance is a major endocrinopathy preceding the development of hyperglycemia, diabetic dyslipidemia and cardiovascular disease in type 2 diabetes. The most common pattern of dyslipidemia in patients with type 2 diabetes are elevated triglyceride levels, decreased hih-density lipoprotein cholesterol and a predominance of small dense low-density lipoprotein particles. Each of these dyslipidemia features is associated with an increased risk of cardiovascular events.
Pioglitazone and Metformin are established drugs which can be used for the treatment of type 2 diabetes. This study will investigate the effects of treatment with fixed Pioglitazone/Metformin combination therapy of Metformin and Glimepiride in Metformin-pretreated type 2 diabetic patients with dyslipidemia.
Total participation time in this study is anticipated to be approximately 24 weeks.
10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 305 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:
Treatment within the last 12 weeks with:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pioglitazone and Metformin
Drug: Glimepiride and Metformin
Drug pages: Pioglitazone · Metformin
Pioglitazone 15 mg/metformin 850 mg combination tablets, orally, twice daily and glimepiride placebo-matching tablets, orally, once daily and metformin placebo-matching tablets, orally, twice daily for up to 24 weeks.
Also known as: ACTOS®, AD-4833, OPIMET
Drug pages: Glimepiride · Metformin
Pioglitazone/metformin placebo-matching combination tablets, orally, twice daily and glimepiride 2 mg, tablets, orally, once daily and metformin 850 mg, tablets, orally, twice daily for up to 24 weeks.
Also known as: Amaryl, Glista
The Mean Increase From Baseline in High-Density Lipoprotein Cholesterol.
The increase in High-Density Lipoprotein (HDL) Cholesterol collected at week 24 or final visit and HDL-Cholesterol collected at baseline.
Time frame: Baseline and Week 24.
Change From Baseline in High-Density Lipoprotein Cholesterol.
The change between HDL-Cholesterol collected at week 24 or final visit and HDL-Cholesterol collected at baseline.
Time frame: Baseline and Week 24.
Change From Baseline in High-Density Lipoprotein/Low-Density Lipoprotein Ratio.
The change between High-Density Lipoprotein/Low-Density Lipoprotein Ratio collected at week 24 or final visit and High-Density Lipoprotein/Low-Density Lipoprotein Ratio collected at baseline.
Time frame: Baseline and Week 24.
Change From Baseline in Triglycerides.
The change between the value of Triglycerides collected at week 24 or final visit and Triglycerides collected at baseline.
Time frame: Baseline and Week 24.
Change From Baseline in Low-Density Lipoprotein Subfractions.
The change between the value of Low-Density Lipoprotein Subfractions collected at week 24 or final visit and Low-Density Lipoprotein Subfractions collected at baseline.
Time frame: Baseline and Week 24.
Change From Baseline in Low-Density Lipoprotein Cholesterol.
The change between Low-Density Lipoprotein Cholesterol collected at week 24 or final visit and Low-Density Lipoprotein Cholesterol collected at baseline.
Time frame: Baseline and Week 24.
Change From Baseline in Glycosylated Hemoglobin.
The change between the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 or final visit and Glycosylated Hemoglobin collected at baseline.
Time frame: Baseline and Week 24.
Change From Baseline in Fasting Intact Proinsulin.
The change between Fasting Intact Proinsulin collected at week 24 or final visit and Fasting Intact Proinsulin collected at baseline.
Time frame: Baseline and Week 24.
Change From Baseline in Fasting Glucose.
The change between Fasting Glucose collected at week 24 or final visit and Fasting Glucose collected at baseline.
Time frame: Baseline and Week 24.
Change From Baseline in Adiponectin.
The change between Adiponectin collected at week 24 or final visit and Adiponectin collected at baseline.
Time frame: Baseline and Week 24.
Change From Baseline in High Sensitivity C-reactive Protein (Original).
The change between the value of High Sensitivity C-reactive Protein collected at week 24 or final visit and High Sensitivity C-reactive Protein collected at baseline.
Time frame: Baseline and Week 24.
Change From Baseline in High Sensitivity C-reactive Protein (≤ 10 mg/L).
The change between the value of High Sensitivity C-reactive Protein less than or equal to 10 mg/L collected at week 24 or final visit and High Sensitivity C-reactive Protein less than or equal to 10 mg/L collected at baseline.
Time frame: Baseline and Week 24.
Change From Baseline in Systolic Blood Pressure.
The change between Systolic Blood Pressure measured at week 24 or final visit and Systolic Blood Pressure measured at baseline.
Time frame: Baseline and Week 24.
Change From Baseline in Diastolic Blood Pressure.
The change between Diastolic Blood Pressure measured at week 24 or final visit and Diastolic Blood Pressure measured at baseline.
Time frame: Baseline and Week 24.
Intake of Study Medication Greater Than 80% and Less Than 120%.
The change between the Intake of study medication greater than 80% at week 24 or final visit and Baseline and the Intake of study medication greater than 80% at baseline.
Time frame: Baseline and Week 24.
Change From Baseline in Nitrotyrosine.
The change between the value of Nitrotyrosine collected at week 24 or final visit and Nitrotyrosine collected at baseline.
Time frame: Baseline and Week 24.
Change From Baseline in Soluble CD40 Ligand.
The change between the value of Soluble CD40 Ligand collected at week 24 or final visit and Soluble CD40 Ligand collected at baseline.
Time frame: Baseline and Week 24.
Change From Baseline in Matrix Metallo Proteinase-9.
The change between the value of Baseline in Matrix Metallo Proteinase-9 collected at week 24 or final visit and Baseline in Matrix Metallo Proteinase-9 collected at baseline.
Time frame: Baseline and Week 24.
Change From Baseline in Soluble Intracellular Adhesion Molecule.
The change between the value of Baseline in Soluble Intracellular Adhesion molecule at week 24 or final visit and Baseline in Soluble Intracellular Adhesion molecule collected at baseline.
Time frame: Baseline and Week 24.
Change From Baseline in Soluble Vascular Cell Adhesion Molecule.
The change between the value of Soluble Vascular Cell Adhesion Molecule collected at week 24 or final visit and Soluble Vascular Cell Adhesion Molecule collected at baseline.
Time frame: Baseline and Week 24.
Change From Baseline in Thromboxane B2.
The change between the value of Thromboxane B2 collected at week 24 or final visit and Thromboxane B2 collected at baseline.
Time frame: Baseline and Week 24.
Change From Baseline in Platelet Function.
The change between the value of Platelet Function by PFA 100 collected at week 24 or final visit and Platelet Function by PFA 100 collected at baseline.
Time frame: Baseline and Week 24.
Change From Baseline in E-Selectin.
The change between the value of E-Selectin collected at week 24 or final visit and E-Selectin collected at baseline.
Time frame: Baseline and Week 24.
Change From Baseline in Von-Willebrand Factor.
The change between the value of Von-Willebrand Factor collected at week 24 or final visit and Von-Willebrand Factor collected at baseline.
Time frame: Baseline and Week 24.
Change From Baseline in Erythrocyte Deformability (0.30%).
The change between the 0.30 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.
Time frame: Baseline and Week 24.
Change From Baseline in Erythrocyte Deformability (0.60%)
The change between the 0.60 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.
Time frame: Baseline and Week 24.
Change From Baseline in Erythrocyte Deformability (1.20).
The change between the 1.20 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.
Time frame: Baseline and Week 24.
Change From Baseline in Erythrocyte Deformability (3.00).
The change between the 3.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.
Time frame: Baseline and Week 24.
Change From Baseline in Erythrocyte Deformability (6.00).
The change between the 6.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.
Time frame: Baseline and Week 24.
Change From Baseline in Erythrocyte Deformability (12.00).
The change between the 12.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.
Time frame: Baseline and Week 24.
Change From Baseline in Erythrocyte Deformability (30.00).
The change between the 30.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.
Time frame: Baseline and Week 24.
Change From Baseline in Erythrocyte Deformability (60.00).
The change between the 60.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.
Time frame: Baseline and Week 24.
Subjects were enrolled at 61 investigative sites in Germany from 03 April 2007 to 13 May 2009.
| Milestone | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID |
|---|---|---|
| Started | 155 | 150 |
| Completed | 123 | 121 |
| Not completed | 32 | 29 |
| Withdrew: Adverse event | 13 | 5 |
| Withdrew: Protocol violation | 8 | 6 |
| Withdrew: Withdrawal by subject | 4 | 7 |
| Withdrew: Lack of compliance | 1 | 4 |
| Withdrew: Worsening of glycosolated hemoglobin | 2 | 2 |
| Withdrew: Fasting glucose > 240 mg/dl | 2 | 1 |
| Withdrew: > three moderate hypoglycemic episodes | 0 | 2 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Physician decision | 1 | 0 |
The increase in High-Density Lipoprotein (HDL) Cholesterol collected at week 24 or final visit and HDL-Cholesterol collected at baseline.
| mg/dL | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID |
|---|---|---|
| The Mean Increase From Baseline in High-Density Lipoprotein Cholesterol. | 3.2 ± 9.7 | -0.3 ± 11.0 |
The change between HDL-Cholesterol collected at week 24 or final visit and HDL-Cholesterol collected at baseline.
| mg/dL | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID |
|---|---|---|
| Change From Baseline in High-Density Lipoprotein Cholesterol. | 3.3 ± 9.6 | -0.4 ± 11.1 |
The change between High-Density Lipoprotein/Low-Density Lipoprotein Ratio collected at week 24 or final visit and High-Density Lipoprotein/Low-Density Lipoprotein Ratio collected at baseline.
| mg/dL | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID |
|---|---|---|
| Change From Baseline in High-Density Lipoprotein/Low-Density Lipoprotein Ratio. | 0.1 ± 0.8 | 0.3 ± 0.7 |
The change between the value of Triglycerides collected at week 24 or final visit and Triglycerides collected at baseline.
| mg/dL | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID |
|---|---|---|
| Change From Baseline in Triglycerides. | -40.9 ± 113.8 | -16.7 ± 121.6 |
The change between the value of Low-Density Lipoprotein Subfractions collected at week 24 or final visit and Low-Density Lipoprotein Subfractions collected at baseline.
| mg/dL | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID |
|---|---|---|
| Change From Baseline in Low-Density Lipoprotein Subfractions. | 6.2 ± 17.5 | 6.1 ± 26.4 |
The change between Low-Density Lipoprotein Cholesterol collected at week 24 or final visit and Low-Density Lipoprotein Cholesterol collected at baseline.
| mg/dL | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID |
|---|---|---|
| Change From Baseline in Low-Density Lipoprotein Cholesterol. | 9.7 ± 34.7 | 11.2 ± 25.3 |
The change between the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 or final visit and Glycosylated Hemoglobin collected at baseline.
| mg/dL | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID |
|---|---|---|
| Change From Baseline in Glycosylated Hemoglobin. | -0.83 ± 0.87 | -0.95 ± 0.85 |
The change between Fasting Intact Proinsulin collected at week 24 or final visit and Fasting Intact Proinsulin collected at baseline.
| pmol/L | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID |
|---|---|---|
| Change From Baseline in Fasting Intact Proinsulin. | -5.18 ± 11.89 | -0.11 ± 9.84 |
The change between Fasting Glucose collected at week 24 or final visit and Fasting Glucose collected at baseline.
| mg/dL | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID |
|---|---|---|
| Change From Baseline in Fasting Glucose. | -21.6 ± 38.6 | -21.1 ± 40.4 |
The change between Adiponectin collected at week 24 or final visit and Adiponectin collected at baseline.
| μg/mL | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID |
|---|---|---|
| Change From Baseline in Adiponectin. | 6.79 ± 6.38 | 0.72 ± 2.73 |
The change between the value of High Sensitivity C-reactive Protein collected at week 24 or final visit and High Sensitivity C-reactive Protein collected at baseline.
| mg/L | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID |
|---|---|---|
| Change From Baseline in High Sensitivity C-reactive Protein (Original). | -0.21 ± 8.98 | -0.04 ± 9.53 |
The change between the value of High Sensitivity C-reactive Protein less than or equal to 10 mg/L collected at week 24 or final visit and High Sensitivity C-reactive Protein less than or equal to 10 mg/L collected at baseline.
| mg/L | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID |
|---|---|---|
| Change From Baseline in High Sensitivity C-reactive Protein (≤ 10 mg/L). | -0.87 ± 1.88 | 0.00 ± 1.83 |
The change between Systolic Blood Pressure measured at week 24 or final visit and Systolic Blood Pressure measured at baseline.
| mmHg | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID |
|---|---|---|
| Change From Baseline in Systolic Blood Pressure. | -2.5 ± 14.8 | 0.5 ± 13.8 |
The change between Diastolic Blood Pressure measured at week 24 or final visit and Diastolic Blood Pressure measured at baseline.
| mmHg | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID |
|---|---|---|
| Change From Baseline in Diastolic Blood Pressure. | -1.3 ± 8.7 | -0.1 ± 8.8 |
The change between the Intake of study medication greater than 80% at week 24 or final visit and Baseline and the Intake of study medication greater than 80% at baseline.
| participants | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID |
|---|---|---|
| Intake of Study Medication Greater Than 80% and Less Than 120%. | 136 | 137 |
The change between the value of Nitrotyrosine collected at week 24 or final visit and Nitrotyrosine collected at baseline.
| nmol/L | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID |
|---|---|---|
| Change From Baseline in Nitrotyrosine. | -2.7 ± 93.2 | 32.5 ± 147.2 |
The change between the value of Soluble CD40 Ligand collected at week 24 or final visit and Soluble CD40 Ligand collected at baseline.
| pg/mL | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID |
|---|---|---|
| Change From Baseline in Soluble CD40 Ligand. | -40.7 ± 248.6 | 102.4 ± 379.8 |
The change between the value of Baseline in Matrix Metallo Proteinase-9 collected at week 24 or final visit and Baseline in Matrix Metallo Proteinase-9 collected at baseline.
| ng/mL | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID |
|---|---|---|
| Change From Baseline in Matrix Metallo Proteinase-9. | 31.4 ± 228.3 | 51.6 ± 216.4 |
The change between the value of Baseline in Soluble Intracellular Adhesion molecule at week 24 or final visit and Baseline in Soluble Intracellular Adhesion molecule collected at baseline.
| ng/mL | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID |
|---|---|---|
| Change From Baseline in Soluble Intracellular Adhesion Molecule. | -13.0 ± 46.9 | -3.2 ± 50.0 |
The change between the value of Soluble Vascular Cell Adhesion Molecule collected at week 24 or final visit and Soluble Vascular Cell Adhesion Molecule collected at baseline.
| ng/mL | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID |
|---|---|---|
| Change From Baseline in Soluble Vascular Cell Adhesion Molecule. | 11.6 ± 160.6 | 3.3 ± 115.4 |
The change between the value of Thromboxane B2 collected at week 24 or final visit and Thromboxane B2 collected at baseline.
| pg/mL | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID |
|---|---|---|
| Change From Baseline in Thromboxane B2. | -216.4 ± 842.9 | 527.8 ± 1190.4 |
The change between the value of Platelet Function by PFA 100 collected at week 24 or final visit and Platelet Function by PFA 100 collected at baseline.
| sec | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID |
|---|---|---|
| Change From Baseline in Platelet Function. | -30.3 ± 44.3 | -1.0 ± 102.5 |
The change between the value of E-Selectin collected at week 24 or final visit and E-Selectin collected at baseline.
| ng/mL | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID |
|---|---|---|
| Change From Baseline in E-Selectin. | -3.7 ± 4.8 | -0.5 ± 3.4 |
The change between the value of Von-Willebrand Factor collected at week 24 or final visit and Von-Willebrand Factor collected at baseline.
| percent | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID |
|---|---|---|
| Change From Baseline in Von-Willebrand Factor. | -19.5 ± 32.0 | 1.4 ± 33.2 |
The change between the 0.30 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.
| percent | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID |
|---|---|---|
| Change From Baseline in Erythrocyte Deformability (0.30%). | 1.3 ± 2.1 | -0.4 ± 1.7 |
The change between the 0.60 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.
| percent | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID |
|---|---|---|
| Change From Baseline in Erythrocyte Deformability (0.60%) | 2.4 ± 1.3 | -0.5 ± 1.1 |
The change between the 1.20 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.
| percent | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID |
|---|---|---|
| Change From Baseline in Erythrocyte Deformability (1.20). | 3.2 ± 2.2 | -1.1 ± 2.5 |
The change between the 3.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.
| percent | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID |
|---|---|---|
| Change From Baseline in Erythrocyte Deformability (3.00). | 3.3 ± 2.8 | -.15 ± 3.1 |
The change between the 6.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.
| percent | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID |
|---|---|---|
| Change From Baseline in Erythrocyte Deformability (6.00). | 3.1 ± 2.9 | -1.4 ± 2.9 |
The change between the 12.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.
| percent | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID |
|---|---|---|
| Change From Baseline in Erythrocyte Deformability (12.00). | 2.7 ± 2.8 | -1.3 ± 2.9 |
The change between the 30.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.
| percent | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID |
|---|---|---|
| Change From Baseline in Erythrocyte Deformability (30.00). | 2.5 ± 2.6 | -1.3 ± 3.5 |
The change between the 60.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.
| percent | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID |
|---|---|---|
| Change From Baseline in Erythrocyte Deformability (60.00). | 2.7 ± 2.6 | -1.3 ± 3.9 |
Collected over 1 year and 11 months. Treatment-emergent adverse events are defined as those occurring after signature of consent form and no more than 14 days after the end of the study.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | — | 17/153 (11.1%) | 61/153 (39.9%) |
| Glimepiride 2 mg and Metformin 850 mg BID | — | 8/149 (5.4%) | 61/149 (40.9%) |
| Event | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID |
|---|---|---|
| Cardiac failureCardiac disorders | 2/153 | 0/149 |
| Abdominal adhesionsGastrointestinal disorders | 0/153 | 1/149 |
| Carotid artery stenosisNervous system disorders | 0/153 | 1/149 |
| Coronary artery diseaseCardiac disorders | 0/153 | 1/149 |
| Hypertensive crisisVascular disorders | 0/153 | 1/149 |
| Peripheral arterial occlusive diseaseVascular disorders | 0/153 | 1/149 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/153 | 1/149 |
| SubileusGastrointestinal disorders | 0/153 | 1/149 |
| Urinary retentionRenal and urinary disorders | 0/153 | 1/149 |
| Benign breast neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/153 | 0/149 |
| Event | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID |
|---|---|---|
| NasopharyngitisInfections and infestations | 24/153 | 33/149 |
| DiarrhoeaGastrointestinal disorders | 14/153 | 14/149 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 8/153 | 3/149 |
| Oedema peripheralGeneral disorders | 8/153 | 4/149 |
| HeadacheNervous system disorders | 7/153 | 7/149 |
| Age Continuous(years) | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID | Total |
|---|---|---|---|
| Mean | 58.7 ± 10.0 | 58.5 ± 9.6 | 58.6 ± 9.8 |
| Sex: Female, Male(Participants) | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID | Total |
|---|---|---|---|
| Female | 54 | 55 | 109 |
| Male | 99 | 94 | 193 |
| Region of Enrollment(participants) | Pioglitazone 15 mg and Metformin 850 mg BID | Glimepiride 2 mg and Metformin 850 mg BID | Total |
|---|---|---|---|
| Germany | 153 | 149 | 302 |
The record gives a start of Apr 2007, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2010, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pioglitazone · Metformin